

# **HHS Public Access**

Ann Intern Med. Author manuscript; available in PMC 2020 January 27.

Published in final edited form as: Ann Intern Med. 2017 May 16; 166(10): 763–764. doi:10.7326/L17-0067.

# Marijuana Use during Stages of Pregnancy in the United States

Nora D. Volkow, M.D.<sup>1</sup>, Beth Han, M.D., Ph.D., M.P.H.<sup>2</sup>, Wilson M. Compton, M.D., M.P.E.<sup>1</sup>, Carlos Blanco, M.D., Ph.D.<sup>1</sup>

<sup>1</sup>·National Institute on Drug Abuse, Bethesda, Maryland <sup>2</sup>·Substance Abuse and Mental Health Services Administration, Rockville, Maryland

# **BACKGROUND AND OBJECTIVE**

Author manuscript

Marijuana is the most frequently used illicit drug during pregnancy (1). Due to concerns regarding potential deleterious effects on neurodevelopment, the American College of Obstetricians and Gynecologists recommends that pregnant women discontinue marijuana consumption. Despite these recommendations, marijuana use increased among adult pregnant and non-pregnant women between 2002 and 2014 (2). Because marijuana use may have different effects across pregnancy trimesters and may be more frequent among pregnant teenagers, we examined prevalence of "past-month marijuana use" among U.S. women during 2002–2015 by pregnancy trimester and sociodemographic characteristics, across the full reproductive age range.

# METHODS

Data were from women aged 12–44 who participated in 2002–2015 National Surveys on Drug Use and Health (NSDUH). NSDUH provides nationally representative data among civilian, noninstitutionalized populations aged 12 or older (3). Among other data, NSDUH collects sociodemographic characteristics, "past-month marijuana use", and "pregnancy status". Respondents who answered "within the past 30 days" to "How long has it been since you last used marijuana or hashish?" were considered "past-month marijuana users". Respondents who answered "yes" to "Are you currently pregnant?" were asked "How many months pregnant are you?" Descriptive analyses were conducted using SUDAAN software to account for NSDUH's complex sample design and sampling weights (3).

Address correspondence to Dr. Nora Volkow, 6001 Executive Blvd., MSC 9589, Bethesda, MD 20892-9589. nvolkow@nida.nih.gov. **Author Contributions:** Dr. Han had full access to all of the data in this study and takes responsibility for integrity of the data and the accuracy of the data analysis.

Acquisition of data: Han.

Drafting of the manuscript: Volkow, Han, Compton.

Statistical analysis: Han.

Study concept and design: Volkow, Han, Compton.

Analysis and interpretation of data: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Obtained funding: N/A.

Administrative, technical, or material support: Han.

**Conflict of Interest Disclosures:** Compton reports ownership of stock in General Electric Co., 3M Co., and Pfizer Inc., unrelated to the submitted work.

# FINDINGS

Among 14,400 pregnant and 395,600 non-pregnant female respondents, self-reported pastmonth marijuana use was less prevalent among pregnant than non-pregnant (3.8% vs. 7.5%, Table 1). Prevalence was higher for the first trimester compared to the second and third (6.4% vs 3.3 and 1.8%).

In both pregnant and non-pregnant groups, self-reported marijuana use was lower among women aged 26 or older than those aged 12–17 or 18–25. Among pregnant women, non-Hispanic blacks had higher prevalence (6.5%) than other racial/ethnic groups (1.4–3.8%). For each examined sociodemographic category, prevalence was higher among non-pregnant than pregnant women, except for youth aged 12–17, where marijuana use was more prevalent among the pregnant than non-pregnant (14.0% vs. 6.5%).

#### DISCUSSION

In the U.S., marijuana use was particularly common in the first trimester (6.4%) when the fetus may be most susceptible to damage from drugs (4), but was also prevalent in the second and third trimesters (3.3% and 1.8% respectively). For most examined sociodemographic categories, prevalence of marijuana use was higher among non-pregnant than pregnant women. However, prevalence of marijuana use was over twofold higher among pregnant than non-pregnant youth, perhaps reflecting underlying risk common to both teen pregnancy and early substance use (5), and suggesting the importance of intervention for teenagers. Because of consistent overlap of marijuana with other substance consumption, identification of marijuana use during pregnancy warrants evaluation for comorbid abuse of other substances (1,2,5).

This study may underestimate marijuana use during pregnancy due to: a) respondents being unaware of pregnancy status; b) respondents using marijuana during pregnancy but not in past month; c) NSDUH excludes homeless women not living in shelters and incarcerated women; and d) recall and social-desirability biases.

Despite these limitations, this study suggests that enhanced prevention against marijuana use and general health promotion efforts should target women attempting to get pregnant or already pregnant, youth, and socioeconomically deprived. Furthermore, reports suggest that some pregnant women are turning to marijuana as an antiemetic, particularly during the first trimester. While evidence for effects of marijuana on human prenatal development is limited, research suggests that there is cause for concern (5), and even with the current uncertainty about marijuana's influence on human neurodevelopment, clinicians should exert caution by not recommending this drug for patients who are pregnant (1). Pregnant women and those considering becoming pregnant should be advised not to use marijuana or other cannabinoids either recreationally or to treat nausea.

### Acknowledgments

**Funding/Support:** The National Surveys on Drug Use and Health were supported by contracts from the Substance Abuse and Mental Health Services Administration.

Ann Intern Med. Author manuscript; available in PMC 2020 January 27.

**Role of the Sponsors:** This study was jointly sponsored by the National Institute on Drug Abuse of the National Institutes of Health and the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services. The sponsors supported the authors who were responsible for preparation, review, and approval of the manuscript and the decision to submit the manuscript for publication. The sponsors had no role in the design and conduct of the study; analysis and interpretation of the data; preparation and review of the manuscript; or decision to submit the manuscript for publication. The sponsors reviewed and approved the manuscript.

**Disclaimers:** The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse of the National Institutes of Health, Substance Abuse and Mental Health Services Administration, or the U.S. Department of Health and Human Services.

#### REFERENCES

- 1. Marijuana use during pregnancy and lactation. Committee Opinion No. 637. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015; 126; 234–8. [PubMed: 26241291]
- Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-age women, 2002–2014. JAMA 2017; 317(2):207– 209. [PubMed: 27992619]
- Center for Behavioral Health Statistics and Quality. (2016). 2014 National Survey on Drug Use and Health: Methodological Resource Book (Section 13, Statistical Inference Report) Substance Abuse and Mental Health Services Administration, Rockville, MD http://www.samhsa.gov/data/sites/ default/files/NSDUHmrbStatInference2014.pdf Accessed October 1, 2016.
- 4. Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA 2017; 317(2):129–130. [PubMed: 27992628]
- Salas-Wright CP, Vaughn MG, Ugalde J, Todic J. Substance use and teen pregnancy in the United States: evidence from the NSDUH 2002–2012. Addict Behav 2015; 45:218–25. [PubMed: 25706068]

#### Table 1.

Self-reported past-month prevalence of marijuana use among women aged 12–44 in the U.S., by pregnancy trimester and sociodemographic characteristics, weighted percentage (95% confidence interval), n=410,000<sup>T</sup>

Characteristics	Pregnant women aged 12–44 weighted % (95% CI) n=14,400	Non-pregnant women aged 12–44 weighted % (95% CI) n=395,600
Overall Annual Average	3.82 (3.41-4.23)	7.54 (7.42–7.66)
Trimester		
1 <sup>st</sup> trimester	6.44 (5.50–7.53)	
2 <sup>nd</sup> trimester	3.34 (2.76–4.05)	
3 <sup>rd</sup> trimester	1.82 (1.41–2.34)	
Age		
12–17	14.02 (11.51–16.99)	6.45 (6.29–6.62)
18–25	6.21 (5.57–6.92)	14.11 (13.85–14.37)
26	1.77 (1.32–2.38)	5.17 (5.00–5.35)
Race/Ethnicity		
Non-Hispanic white	3.82 (3.31–4.40)	8.44 (8.27–8.62)
Non-Hispanic black	6.45 (5.13–8.07)	8.00 (7.66–8.35)
Non-Hispanic other	1.39 (1.00–1.94)	5.12 (4.79–5.46)
Hispanic	2.92 (2.17–3.92)	5.22 (4.98–5.47)
Annual Family Income		
<\$20,000	6.57 (5.60–7.70)	10.80 (10.50–11.11)
\$20,000-\$49,999	3.90 (3.28–4.62)	7.76 (7.55–7.98)
\$50,000-\$74,999	2.80 (1.95-4.00)	6.19 (5.91–6.48)
\$75,000	1.86 (1.31–2.63)	5.64 (5.44–5.85)
Health Insurance Status		
Private insurance only	1.82 (1.42–2.34)	6.49 (6.34–6.64)
Uninsured	7.87 (5.85–10.52)	9.46 (9.13–9.81)
Medicaid	5.55 (4.89–6.30)	9.35 (9.04–9.66)
Other insurance	4.65 (2.94–7.28)	8.08 (7.59–8.60)
Census Region		
Northeast	3.21 (2.53–4.06)	8.67 (8.38–8.97)
Midwest	3.36 (2.79–4.05)	7.53 (7.30–7.76)
South	4.33 (3.65–5.14)	6.35 (6.15–6.56)
West	3.90 (2.98–5.07)	8.55 (8.25-8.86)
Metropolitan Statistical Area		
Large metro	3.34 (2.81–3.96)	7.76 (7.58–7.95)
Small metro	4.58 (3.88–5.41)	7.65 (7.44–7.86)

Ann Intern Med. Author manuscript; available in PMC 2020 January 27.

Characteristics	Pregnant women aged 12–44 weighted % (95% CI) n=14,400	Non-pregnant women aged 12–44 weighted % (95% CI) n=395,600
Nonmetro	3.95 (3.17–4.90)	6.50 (6.23–6.78)

Data source: The 2002–2015 National Surveys on Drug Use and Health (NSDUH). CI=Confidence Interval.

I: SAMHSA requires that any description of overall sample size based on the restricted-use data files be rounded to the nearest 100 to minimize potential disclosure risk. P-values from overall between group comparisons (pregnant women vs. non-pregnant women) for each characteristic were all <0.001. After using a Bonferroni correction to account for the 7 tests, all between group comparisons continued to reach statistical significance at the 0.05 level.